Treatment of bone metastases in breast cancer: An update

被引：1

作者：

Myra F. Barginear

Catherine H. Van Poznak

机构：

[1] Monter Cancer Center of the North Shore-LIJ Cancer Institute, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY 11042

[2] University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5848

来源：

Current Breast Cancer Reports | 2012年 / 4卷 / 4期

关键词：

Antiresorptive agents; Bisphosphonates; Bone metastases; Bone modifying agents; Bone turnover markers; Breast cancer; Denosumab; Imaging; Interventions; Monitoring; Radiation therapy; Radiopharmaceuticals; Skeletal metastases; Skeletal related events; SREs; Surgery; Treatment;

D O I：

10.1007/s12609-012-0089-1

中图分类号：

学科分类号：

摘要：

Bone is the most common site of breast cancer metastases. When breast cancer has metastasized to bone, it is considered an incurable disease. Osseous metastases are associated with significant morbidities including pain, pathological fractures, hypercalcemia of malignancy, and spinal cord compression. In this setting, the palliative goals of care include preventing skeletal related events, managing complications, reducing bone pain, and improving quality of life. Antiresorptive agents such as bisphosphonates have been the mainstay of bone-directed treatment, along with radiation therapy, and surgery. Most recently, RANKL-inhibitors have become another tool in the treatment of bone metastases. This review discusses bone-modifying agents and other targeted interventions in breast cancer patients with skeletal metastases. © Springer Science+Business Media, LLC 2012.

引用

页码：257 / 263

页数：6

共 47 条

[11]

q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (bc) after 1 yr of standard zol treatment, J Clin Oncol, 30, SUPPL., (2012)

[12]

Study Of Zoledronic Acid Administered Monthly Vs, (2012)

[13]

Zoledronic Acid In Treating Patients With Metastatic Breast Cancer Metastatic Prostate Cancer Or Multiple Myeloma With Bone Involvement

[14]

Van Poznak C.H., Von Roenn J.H., Temin S., American society of clinical oncology clinical practice guideline update: Recommendations on the role of bone-modifying agents in metastatic breast cancer, J Oncol Pract, 7, pp. 117-21, (2011)

[15]

Aapro M., Abrahamsson P.A., Body J.J., Et al., Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel, Ann Oncol, 19, pp. 420-32, (2008)

[16]

Stopeck A.T., Lipton A., Body J.J., Et al., Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized double-blind study, J Clin Oncol, 28, pp. 5132-9, (2010)

[17]

Aapro M.S., Denosumab for bone metastases from breast cancer: A new therapy option?, J Clin Oncol, 29, (2011)

[18]

Lipton A S.S., Rader M., Comparison of denosumab vs zoledronic acid for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials, Presented at the proeedings of the 35th ESMO Congress

[19]

Stopeck A., Richardson G., Sienac S., Lipton A., Browne J., Fizazif K., Et al., Aos13 denosumab vs zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of 3 phase 3 studies, Eur J Cancer, 48, (2012)

[20]

Bonomi M., Nortilli R., Molino A., Et al., Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: A long-term retrospective analysis, Med Oncol, 27, pp. 224-9, (2010)

← 1 2 3 4 5 →